Details
Stereochemistry | RACEMIC |
Molecular Formula | C22H22FN3O2.C3H6O3 |
Molecular Weight | 469.5053 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)C(O)=O.FC1=CC=C(C=C1)C(=O)CCCN2CCC(=CC2)N3C(=O)NC4=CC=CC=C34
InChI
InChIKey=CUYSTLHETVVORS-UHFFFAOYSA-N
InChI=1S/C22H22FN3O2.C3H6O3/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28;1-2(4)3(5)6/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28);2,4H,1H3,(H,5,6)
DescriptionSources: http://www.drugbank.ca/drugs/DB00450Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/droperidol.html
Sources: http://www.drugbank.ca/drugs/DB00450
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/droperidol.html
Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias. The exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine (2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well. Droperidol is used to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
CNS Activity
Sources: http://www.drugbank.ca/drugs/DB00450
Curator's Comment: Droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 Sources: http://www.drugbank.ca/drugs/DB00450 |
|||
Target ID: CHEMBL229 Sources: http://www.drugbank.ca/drugs/DB00450 |
|||
Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12190308 |
32.2 nM [IC50] | ||
Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2879412 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | INAPSINE Approved UseDroperidol injection is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures. Launch Date1970 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.5 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
26.6 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.7 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
40 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.4 mg/kg multiple, oral Dose: 0.4 mg/kg Route: oral Route: multiple Dose: 0.4 mg/kg Sources: |
unhealthy, 2-9 years Health Status: unhealthy Age Group: 2-9 years Sources: |
Disc. AE: QT interval prolonged... AEs leading to discontinuation/dose reduction: QT interval prolonged Sources: |
8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Other AEs: Asthenia, Chills... Other AEs: Asthenia (24.6%) Sources: Chills (3.3%) Anorexia (3.3%) Akathisia (16.4%) Anxiety (27.9%) Confusion (3.3%) Dizziness (9.8%) Dry mouth (9.8%) Nervousness (4.9%) Paresthesia (3.3%) Somnolence (24.6%) Tremor (1.6%) Pharyngitis (4.9%) Rhinitis (4.9%) Sweaty (8.2%) |
2.5 mg multiple, intravenous (starting) Dose: 2.5 mg Route: intravenous Route: multiple Dose: 2.5 mg Sources: |
unhealthy |
Disc. AE: Torsades de pointes... AEs leading to discontinuation/dose reduction: Torsades de pointes Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
QT interval prolonged | Disc. AE | 0.4 mg/kg multiple, oral Dose: 0.4 mg/kg Route: oral Route: multiple Dose: 0.4 mg/kg Sources: |
unhealthy, 2-9 years Health Status: unhealthy Age Group: 2-9 years Sources: |
Tremor | 1.6% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Akathisia | 16.4% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Asthenia | 24.6% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Somnolence | 24.6% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Anxiety | 27.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Anorexia | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Chills | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Confusion | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Paresthesia | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Nervousness | 4.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Pharyngitis | 4.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Rhinitis | 4.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Sweaty | 8.2% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Dizziness | 9.8% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Dry mouth | 9.8% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Torsades de pointes | Disc. AE | 2.5 mg multiple, intravenous (starting) Dose: 2.5 mg Route: intravenous Route: multiple Dose: 2.5 mg Sources: |
unhealthy |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 19.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
major |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
[Postoperative nausea and vomiting--still a problem?]. | 2001 |
|
[The influence of age on hemodynamics and the dose requirements of propofol and buprenorphine in total intravenous anesthesia combined with continuous epidural anesthesia]. | 2001 Aug |
|
Effects of dopamine antagonists in human eye accommodation. | 2001 Feb |
|
Suppression of potassium conductance by droperidol has influence on excitability of spinal sensory neurons. | 2001 Feb |
|
Prevention of postoperative nausea and vomiting with antiemetics in patients undergoing middle ear surgery: comparison of a small dose of propofol with droperidol or metoclopramide. | 2001 Jan |
|
[Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo]. | 2001 Jul |
|
Plasma glucocorticoid concentrations after fentanyl-droperidol, ketamine-xylazine and ketamine-diazepam anaesthesia in New Zealand white rabbits. | 2001 Jun 23 |
|
Impact of antiemetic selection on postoperative nausea and vomiting and patient satisfaction. | 2001 May |
|
[Postoperative nausea--still a problem]. | 2001 Oct 3 |
|
Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. | 2002 |
|
Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro-Brazil: a prevalence study. | 2002 |
|
The black box warning. | 2002 Fall |
|
Four-step local anesthesia and sedation for thoracoscopic diagnosis and management of pleural diseases. | 2002 Jun |
|
[Effects of preincisional epidural administration of lidocaine and fentanyl on postoperative pain management following hysterectomy]. | 2002 Jun 10 |
|
Derivative spectrophotometric determination of droperidol in presence of parabens. | 2002 Jun 20 |
|
Superior prolonged antiemetic prophylaxis with a four-drug multimodal regimen - comparison with propofol or placebo. | 2002 Mar |
|
Treatment patterns of isolated benign headache in US emergency departments. | 2002 Mar |
|
Black-box warning for droperidol surprises pharmacists. | 2002 Mar 15 |
|
Using imprecise probabilities to address the questions of inference and decision in randomized clinical trials. | 2002 May |
|
Acute dystonia by droperidol during intravenous patient-controlled analgesia in young patients. | 2002 Oct |
|
Effects of anesthesia on efferent-mediated adaptation of the DPOAE. | 2002 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/droperidol.html
Curator's Comment: Intravenous or Intramuscular
Dosage: The dosage should be individualized. Factors to be considered in determining dose are age, body weight, physical status, underlying pathological condition, use of other drugs, the type of anesthesia to be used, and the surgical procedure involved. Vital signs and ECG should be monitored closely.
Maximum Dosage: The maximum recommended initial dose is 2.5 mg IM or slow IV. Additional 1.25 mg doses of droperidol may be administered to achieve the desired effect. The additional doses should be administered with caution and only if the potential benefit outweighs the potential risk.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16492829
Droperidol (10(-7) M) caused vasodilator effect (approximately 20% of vasorelaxation compared with maximal vasorelaxation induced by papaverine [3 x 10(-4) M] in rat vascular smooth muscle cells.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB01839MIG
Created by
admin on Sat Dec 16 09:00:02 GMT 2023 , Edited by admin on Sat Dec 16 09:00:02 GMT 2023
|
PRIMARY | |||
|
9956314
Created by
admin on Sat Dec 16 09:00:02 GMT 2023 , Edited by admin on Sat Dec 16 09:00:02 GMT 2023
|
PRIMARY | |||
|
09NO5N37E0
Created by
admin on Sat Dec 16 09:00:02 GMT 2023 , Edited by admin on Sat Dec 16 09:00:02 GMT 2023
|
PRIMARY | |||
|
100000087719
Created by
admin on Sat Dec 16 09:00:02 GMT 2023 , Edited by admin on Sat Dec 16 09:00:02 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD